DICE Announces Pricing of Upsized Public Offering of Common

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical firm leveraging its proprietary know-how platform to construct a pipeline of novel oral therapeutic candidates to deal with continual illnesses in immunology and different therapeutic areas, immediately introduced the pricing of its upsized underwritten public providing of 8,219,178 shares of its widespread inventory at a public providing worth of $36.50 per share. All shares of widespread inventory are being supplied by DICE. The gross proceeds to DICE from the providing, earlier than deducting underwriting reductions and commissions and different providing bills, are anticipated to be roughly $300.0 million. In addition, DICE has granted the underwriters a 30-day choice to buy as much as a further 1,232,876 shares of its widespread inventory on the public providing worth, much less underwriting reductions and commissions. The providing is predicted to shut on or about October 17, 2022, topic to the satisfaction of customary closing circumstances.

BofA Securities, SVB Securities, Evercore ISI and Guggenheim Securities are performing because the joint book-running managers for the providing.

The securities are being supplied by DICE pursuant to a registration assertion on Form S-3 beforehand filed and declared efficient by the Securities and Exchange Commission (SEC). A closing prospectus complement and accompanying base prospectus referring to and describing the phrases of the providing will probably be filed with the SEC and will probably be accessible on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and accompanying base prospectus might also be obtained, when accessible, from: BofA Securities, NC1-004-03-43, 200 North College Street, third Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by e-mail at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, fortieth Floor, Boston, Massachusetts 02109, by phone at (800) 808-7525, ext. 6105, or by e-mail at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, thirty sixth Floor, New York, New York 10055, by phone at (888) 474-0200, or by e-mail at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, eighth Floor, New York, New York 10017, by phone at (212) 518-9544, or by e-mail at [email protected].

This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase, nor shall there be any sale of these securities in any state or jurisdiction by which such supply, solicitation, or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc. is a biopharmaceutical firm leveraging its proprietary know-how platform to construct a pipeline of novel oral therapeutic candidates to deal with continual illnesses in immunology and different therapeutic areas. DICE is initially centered on creating oral therapeutics towards well-validated targets in immunology, with the purpose of reaching comparable efficiency to their systemic biologic counterparts, which have demonstrated the best therapeutic profit up to now in these illness areas. The Company’s DELSCAPE platform is designed to find selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as successfully as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug goal implicated in a spread of immunology indications. DICE can also be creating oral therapeutic candidates concentrating on α4ß7 integrin and αVß1/αVß6 integrin for the remedy of inflammatory bowel illness and idiopathic pulmonary fibrosis, respectively.

Cautionary Note Regarding Forward-Looking Statements

This press launch incorporates forward-looking statements throughout the that means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements mirror the present beliefs and expectations of administration and embody, however will not be restricted to, statements relating to the timing, dimension and anticipated gross proceeds of the providing, the satisfaction of customary closing circumstances associated to the providing and sale of securities, and the Company’s means to finish the providing. In addition, when or if used on this press launch, the phrases “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and comparable expressions and their variants, as they relate to the Company could establish forward-looking statements. Forward-looking statements are neither historic details nor assurances of future efficiency. Although the Company believes the expectations mirrored in such forward-looking statements are affordable, the Company can provide no assurance that such expectations will show to be appropriate. Readers are cautioned that precise outcomes, ranges of exercise, security, efficiency or occasions and circumstances may differ materially from these expressed or implied within the Company’s forward-looking statements resulting from a spread of components, together with dangers and uncertainties associated to market circumstances and the satisfaction of closing circumstances associated to the general public providing, the Company’s means to advance DC-806, DC-853 and its different therapeutic candidates, receive regulatory approval of and finally commercialize the Company’s therapeutic candidates, the timing and outcomes of preclinical and scientific trials, the Company’s means to fund improvement actions and obtain improvement objectives, the influence of the COVID-19 pandemic on the Company’s business, its means to guard its mental property and different dangers and uncertainties described underneath the heading “Risk Factors” in paperwork the Company recordsdata every so often with the SEC, together with the Company’s quarterly report on Form 10-Q filed on August 11, 2022, the preliminary prospectus complement referring to this providing, and its different SEC filings. Accordingly, readers are cautioned to not place undue reliance on these forward-looking statements. Except as required by relevant regulation, we don’t plan to publicly replace or revise any forward-looking statements contained herein.

Contacts:

Katie Engleman, 1AB

[email protected]

Investors:

[email protected]